Estrogen receptor activation has been examined in murine uteri by characterizing binding to ATP-Sepharose. Determinations were performed under conditions in which specific binding to estrogen receptors was demonstrated by both agonist and antagonist without participation by nonreceptor antiestrogen-binding components. Cell-free activation of estrogen receptors in cytosol was more effectively promoted by [3H]estradiol estradiol than by [3H]4-hydroxytamoxifen or [3H]tamoxifen aziridine. However, when in situ activation was examined after intact uteri were exposed to [3H]estradiol or [3H]4-hydroxytamoxifen, virtually all extracted nuclear receptors demonstrated activated binding to ATP-Sepharose within 20 min of hormone exposure. Profiles of nuclear receptor activation were remarkably similar after exposure to either agonist or antagonist. Estrogen receptors in cytosol prepared after exposing intact uteri to 3H-labeled ligands were characterized by much less ability to bind to ATP-Sepharose than nuclear receptors. After uteri were exposed to [3H]estradiol, the activated receptor fraction in the cytosol progressively increased in contrast to preparations obtained after uteri were exposed to [3H]4-hydroxytamoxifen, which demonstrated a constant level of activation. Thus, even when activation has occurred within the intact uterus, agonists and antagonists may be characterized by different apparent levels of receptor activation in the cytosol fraction. These differences in the cytosol, however, are considerably overshadowed by the extensive activation occurring within the nuclear fraction, which we have observed to be similar with agonist and antagonist. Since estrogen receptors appear to act within chromatin, and cytosol receptors may be produced by receptor redistribution during preparation, we interpret these observations to indicate that in situ receptor activation is very similar after exposure to either agonist or antagonist. Consequently, antagonism does not appear to be associated with antiestrogens that impede receptor activation within intact murine uteri.

Download full-text PDF

Source
http://dx.doi.org/10.1210/endo-120-4-1608DOI Listing

Publication Analysis

Top Keywords

estrogen receptors
20
receptor activation
20
agonist antagonist
16
murine uteri
12
uteri exposed
12
activation
11
situ activation
8
receptors
8
[3h]estradiol [3h]4-hydroxytamoxifen
8
activation examined
8

Similar Publications

An aggressive angiomyxoma (AA) is a rare soft tissue neoplasm of the lower female genital tract. The incidence of vaginal involvement is low, so it is commonly misdiagnosed as a Bartholin cyst, lipoma, and abscess, among others. This is a case of a 31-year-old female patient presenting with anterior vaginal wall swelling measuring 1 x 1 cm, clinically diagnosed as vaginal carbuncle.

View Article and Find Full Text PDF

Recent evidence indicates that endocrine resistance in estrogen receptor-positive (ER+) breast cancer is closely correlated with phenotypic characteristics of epithelial-to-mesenchymal transition (EMT). Nonetheless, identifying tumor tissues with a mesenchymal phenotype remains challenging in clinical practice. In this study, we validated the correlation between EMT status and resistance to endocrine therapy in ER+ breast cancer from a transcriptomic perspective.

View Article and Find Full Text PDF

Background: Vulvodynia is a multifactorial disease affecting 7%-16% of reproductive-aged women in general population; however, little is still known about the genetics underlying this complex disease.

Aim: To compare polygenic risk scores for hormones and receptors levels in a case-control study to investigate their role in vulvodynia and their correlation with clinical phenotypes.

Methods: Our case-control study included patients with vestibulodynia (VBD) and healthy women.

View Article and Find Full Text PDF

Background: Proteasomes degrade intracellular proteins. Different proteasome forms were identified. Proteasome inhibitors are used in cancer therapy, and novel drugs directed to specific proteasome forms are developed.

View Article and Find Full Text PDF
Article Synopsis
  • Ovarian cancer is a major cause of cancer-related deaths in women, with both genetic and epigenetic factors contributing to its development and progression.
  • Estrogen signaling plays a significant role in ovarian cancer, involving estrogen receptors and their regulation of genes related to cell growth and death, influenced by epigenetic changes like histone modifications and DNA methylation.
  • This review summarizes current knowledge on these epigenetic mechanisms and explores the potential of epigenetic therapies as treatment options for ovarian cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!